NovaBay Pharmaceuticals, Inc. (NBY)
NYSEAMERICAN: NBY · Real-Time Price · USD
0.5702
0.00 (0.00%)
Apr 25, 2025, 4:00 PM EDT - Market closed
NovaBay Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 9.75 | 10.46 | 14.37 | 10.18 | 9.92 | Upgrade
|
| Other Revenue | 0.03 | - | 0.03 | 0.02 | 0.02 | Upgrade
|
| Revenue | 9.78 | 10.46 | 14.4 | 10.2 | 9.93 | Upgrade
|
| Revenue Growth (YoY) | -6.45% | -27.42% | 41.16% | 2.72% | 50.54% | Upgrade
|
| Cost of Revenue | 3.3 | 4.37 | 6.62 | 3.69 | 3.97 | Upgrade
|
| Gross Profit | 6.48 | 6.08 | 7.78 | 6.52 | 5.96 | Upgrade
|
| Selling, General & Admin | 11.41 | 10.15 | 15.29 | 15.33 | 12.11 | Upgrade
|
| Research & Development | 0.04 | 0.03 | 0.17 | 0.04 | 0.29 | Upgrade
|
| Operating Expenses | 11.46 | 10.19 | 15.46 | 15.38 | 12.39 | Upgrade
|
| Operating Income | -4.97 | -4.1 | -7.68 | -8.86 | -6.43 | Upgrade
|
| Interest Expense | -0.9 | -1.69 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -0.44 | -0.39 | 3.25 | 3.04 | -5.51 | Upgrade
|
| EBT Excluding Unusual Items | -6.31 | -6.19 | -4.43 | -5.82 | -11.93 | Upgrade
|
| Impairment of Goodwill | - | - | -4.18 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.87 | - | - | - | - | Upgrade
|
| Asset Writedown | - | - | -2.56 | - | - | Upgrade
|
| Other Unusual Items | -0.03 | 0.04 | 0.56 | - | 0.9 | Upgrade
|
| Pretax Income | -7.21 | -6.15 | -10.61 | -5.82 | -11.03 | Upgrade
|
| Income Tax Expense | - | - | - | - | 0.01 | Upgrade
|
| Earnings From Continuing Operations | -7.21 | -6.15 | -10.61 | -5.82 | -11.04 | Upgrade
|
| Earnings From Discontinued Operations | -0.01 | -3.5 | - | - | - | Upgrade
|
| Net Income | -7.22 | -9.64 | -10.61 | -5.82 | -11.04 | Upgrade
|
| Preferred Dividends & Other Adjustments | 1.39 | 7.06 | 5.66 | 0.74 | - | Upgrade
|
| Net Income to Common | -8.61 | -16.7 | -16.27 | -6.56 | -11.04 | Upgrade
|
| Shares Outstanding (Basic) | 3 | 0 | 0 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 3 | 0 | 0 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 2730.00% | 160.87% | 29.11% | 24.43% | 62.08% | Upgrade
|
| EPS (Basic) | -2.53 | -139.14 | -353.59 | -184.09 | -385.53 | Upgrade
|
| EPS (Diluted) | -2.53 | -139.14 | -353.59 | -184.09 | -385.53 | Upgrade
|
| Free Cash Flow | -5.4 | -4.65 | -6.77 | -9.24 | -4.75 | Upgrade
|
| Free Cash Flow Per Share | -1.59 | -38.77 | -147.09 | -259.45 | -165.79 | Upgrade
|
| Gross Margin | 66.26% | 58.19% | 54.02% | 63.85% | 60.04% | Upgrade
|
| Operating Margin | -50.85% | -39.23% | -53.32% | -86.85% | -64.69% | Upgrade
|
| Profit Margin | -88.01% | -159.70% | -112.92% | -64.28% | -111.12% | Upgrade
|
| Free Cash Flow Margin | -55.16% | -44.51% | -46.97% | -90.59% | -47.78% | Upgrade
|
| EBITDA | -4.93 | -4.05 | -7.2 | -8.74 | -6.38 | Upgrade
|
| EBITDA Margin | -50.44% | -38.75% | -49.96% | -85.68% | -64.17% | Upgrade
|
| D&A For EBITDA | 0.04 | 0.05 | 0.48 | 0.12 | 0.05 | Upgrade
|
| EBIT | -4.97 | -4.1 | -7.68 | -8.86 | -6.43 | Upgrade
|
| EBIT Margin | -50.85% | -39.23% | -53.32% | -86.85% | -64.69% | Upgrade
|
| Revenue as Reported | 9.78 | 10.46 | 14.4 | 10.2 | 9.93 | Upgrade
|
| Advertising Expenses | 0.7 | 1.1 | 2 | 3.2 | 1.7 | Upgrade
|
Updated Nov 7, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.